While this happened, CapitalOne initiated its Immutep Limited ADR [IMMP] rating to an Overweight in a research note published on May 17, 2024; the price target was $10. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early August with a ‘”an Outperform”‘ rating. Ladenburg Thalmann began covering IMMP with “Buy” recommendation on August 03, 2021.
Price Performance Review of IMMP
On Monday, Immutep Limited ADR [NASDAQ:IMMP] saw its stock jump 45.61% to $2.49. Over the last five days, the stock has gained 50.91%. Immutep Limited ADR shares have risen nearly 14.75% since the year began. Nevertheless, the stocks have fallen -6.74% over the past one year. While a 52-week high of $3.34 was reached on 05/05/25, a 52-week low of $1.32 was recorded on 04/07/25. SMA at 50 days reached $1.7200, while 200 days put it at $2.0000.
Levels Of Support And Resistance For IMMP Stock
The 24-hour chart illustrates a support level at 2.0300, which if violated will result in even more drops to 1.5700. On the upside, there is a resistance level at 2.8300. A further resistance level may holdings at 3.1700. The Relative Strength Index (RSI) on the 14-day chart is 80.20, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.2800, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 17.35%. Stochastics %K at 73.34% indicates the stock is a holding.
How much short interest is there in Immutep Limited ADR?
A steep rise in short interest was recorded in Immutep Limited ADR stocks on 2025-04-15, dropping by -0.62 million shares to a total of 4.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 4.75 million shares. There was a decline of -15.03%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 28, 2018 when B. Riley FBR began covering the stock and recommended ‘”a Buy”‘ rating along with a $7.75 price target.
